Hepatobiliary Division of Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India.
Department of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India.
J Surg Oncol. 2024 May;129(6):1121-1130. doi: 10.1002/jso.27600. Epub 2024 Feb 13.
Neuroendocrine neoplasms (NENs) are classified as neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), and mixed neuroendocrine and nonneuroendocrine neoplasms (MiNENs) according to World Health Organization classification. We present our experience of NENs of the gallbladder (GB) from a high-volume cancer hospital.
The present study is a retrospective analysis of all patients with GB NENs who presented between January 2015 and June 2023. The patient details and treatment received with follow-up were noted. The primary endpoint was overall survival (OS).
A total of 147 patients were included in the study. The median age was 52 (27-81) years. There was a female predominance (70.7%). NEC was the most common subtype (84.4%) followed by MiNEN (12.9%) and NET (2.7%). The most common stage at presentation was metastatic (70.7%) followed by locally advanced (21.8%), and early disease (7.5%). The median follow-up was 9.92 (1.77-76.06) months. Median OS was 6.14 (3.93-8.35) months. Median OS in patients who received multimodality treatment was 20.20 (17.99-22.41) months versus 4.00 (2.91-5.10) months in those who did not receive it.
GB NENs are rare, but aggressive tumors with NEC being the most common type. Multimodality treatment yields favorable outcomes. However, the development of better systemic therapy is needed to help improve survival further.
神经内分泌肿瘤（NENs）根据世界卫生组织分类可分为神经内分泌肿瘤（NETs）、神经内分泌癌（NECs）和混合性神经内分泌-非神经内分泌肿瘤（MiNENs）。我们报告了一家高容量癌症医院的胆囊（GB）神经内分泌肿瘤（NENs）的经验。
本研究是对 2015 年 1 月至 2023 年 6 月期间就诊的所有 GB NENs 患者的回顾性分析。记录了患者的详细资料和接受的治疗及随访情况。主要终点是总生存期（OS）。
共纳入 147 例患者。中位年龄为 52 岁（27-81 岁）。女性占优势（70.7%）。最常见的亚型是 NEC（84.4%），其次是 MiNEN（12.9%）和 NET（2.7%）。最常见的分期为转移性（70.7%），其次是局部晚期（21.8%）和早期疾病（7.5%）。中位随访时间为 9.92 个月（1.77-76.06）。中位 OS 为 6.14 个月（3.93-8.35）。接受多模式治疗的患者中位 OS 为 20.20 个月（17.99-22.41），而未接受治疗的患者中位 OS 为 4.00 个月（2.91-5.10）。
GB NENs 较为罕见，但为侵袭性肿瘤，NEC 是最常见的类型。多模式治疗可获得良好的结果。然而，需要开发更好的系统治疗方法来进一步提高生存率。
